Research programme: small molecule respiratory disorder therapeutics - Axikin Pharmaceuticals

Drug Profile

Research programme: small molecule respiratory disorder therapeutics - Axikin Pharmaceuticals

Alternative Names: AXP-AO; AXP-D; AXP-E

Latest Information Update: 17 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare
  • Developer Axikin Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action CCR3 receptor antagonists; G protein-coupled receptor antagonists; Immunosuppressants; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Allergic asthma
  • Research Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 17 Jul 2013 Axikin Pharmaceuticals plans a phase II trial for Allergic asthma in Canada (NCT01890161)
  • 01 Jun 2013 Preclinical trials in Allergic asthma in USA (PO)
  • 29 Mar 2010 Research is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top